A metabolomic signature of treated and drug-naïve patients with Parkinson’s disease: a pilot study
About 90% of cases of Parkinson’s disease (PD) are idiopathic and attempts to understand pathogenesis typically assume a multifactorial origin. Multifactorial diseases can be studied using metabolomics, since the cellular metabolome reflects the interplay between genes and environment.
The aim of our case–control study is to compare metabolomic profiles of whole blood obtained from treated PD patients, de-novo PD patients and controls, and to study the perturbations correlated with disease duration, disease stage and motor impairment.
We collected blood samples from 16 drug naïve parkinsonian patients, 84 treated parkinsonian patients, and 42 age matched healthy controls. Metabolomic profiles have been obtained using gas chromatography coupled to mass spectrometry. Multivariate statistical analysis has been performed using supervised models; partial least square discriminant analysis and partial least square regression.
This approach allowed separation between discrete classes and stratification of treated patients according to continuous variables (disease duration, disease stage, motor score). Analysis of single metabolites and their related metabolic pathways revealed unexpected possible perturbations related to PD and underscored existing mechanisms that correlated with disease onset, stage, duration, motor score and pharmacological treatment.
Metabolomics can be useful in pathogenetic studies and biomarker discovery. The latter needs large-scale validation and comparison with other neurodegenerative conditions.
KeywordsMetabolome Parkinson’s disease Gas chromatography–mass spectrometry
We are grateful to prof. Steven Symes who supported the linguistic revision of the paper. The study was supported by “Fondazione Grigioni per il Morbo di Parkinson”.
JT, AL, PB and MA conceived the study. JT and AL wrote the first draft of the manuscript. MA and PB reviewed and critiqued the drafts. JT conceived and performed statistical analysis. CV, KL, MS, AC, MCS and MA recruited the patients and performed the clinical evaluation. All the authors read, critiqued and approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
All the authors have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the local ethics committee and a written consent form was signed by each participant.
- Bertoncini, C. W., Fernandez, C. O., Griesinger, C., Jovin, T. M., & Zweckstetter, M. (2005). Familial mutants of α-synuclein with increased neurotoxicity have a destabilized conformation. Journal of Biological Chemistry, 280(35), 30649–30652. https://doi.org/10.1074/jbc.C500288200.CrossRefPubMedGoogle Scholar
- Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R., & Griffin, J. L. (2011). Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society Reviews, 40(1), 387–426. https://doi.org/10.1039/b906712b.CrossRefPubMedGoogle Scholar
- Han, W., Sapkota, S., Camicioli, R., Dixon, R. A., & Li, L. (2017). Profiling novel metabolic biomarkers for Parkinson’s disease using in-depth metabolomic analysis. Movement Disorders : Official Journal of the Movement Disorder Society, 32(12), 1720–1728. https://doi.org/10.1002/mds.27173.CrossRefGoogle Scholar
- Karnovsky, A., Weymouth, T., Hull, T., Tarcea, V. G., Scardoni, G., Laudanna, C., et al. (2012). Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics (Oxford, England), 28(3), 373–380. https://doi.org/10.1093/bioinformatics/btr661.CrossRefGoogle Scholar
- Kuhn, M. (2008). Building Predictive Models in R Using the caret Package. Journal of Statistical Software, 1(5). https://www.jstatsoft.org/v028/i05
- Luan, H., Liu, L.-F., Tang, Z., Zhang, M., Chua, K.-K., Song, J.-X., et al. (2015). Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson’s disease. Scientific Reports, 5, 13888. https://doi.org/10.1038/srep13888.CrossRefPubMedPubMedCentralGoogle Scholar
- Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016). The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: A mini review. Oxidative Medicine and Cellular Longevity, 2016, 8590578. https://doi.org/10.1155/2016/8590578.CrossRefPubMedPubMedCentralGoogle Scholar
- Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., et al. (2011). Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell, 146(1), 37–52. https://doi.org/10.1016/j.cell.2011.06.001.CrossRefPubMedPubMedCentralGoogle Scholar
- Mevik, B.-H., & Wehrens, R. (2007). The pls package: Principal component and partial least squares regression in R. Journal of Statistical Software, 1(2). https://www.jstatsoft.org/v018/i02
- Noyce, A. J., Bestwick, J. P., Silveira-Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., et al. (2012). Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 72(6), 893–901. https://doi.org/10.1002/ana.23687.CrossRefPubMedPubMedCentralGoogle Scholar
- Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell, 167(6), 1469–1480.e12. https://doi.org/10.1016/j.cell.2016.11.018.CrossRefPubMedPubMedCentralGoogle Scholar
- Sharma, S., Taliyan, R., & Singh, S. (2015). Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity. Behavioural Brain Research, 291, 306–314. https://doi.org/10.1016/j.bbr.2015.05.052.CrossRefPubMedGoogle Scholar
- St Laurent, R., O’Brien, L. M., & Ahmad, S. T. (2013). Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson’s disease. Neuroscience, 246, 382–390. https://doi.org/10.1016/j.neuroscience.2013.04.037.CrossRefPubMedPubMedCentralGoogle Scholar
- Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., et al. (2007). Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics : Official Journal of the Metabolomic Society, 3(3), 211–221. https://doi.org/10.1007/s11306-007-0082-2.CrossRefGoogle Scholar
- Trezzi, J.-P., Galozzi, S., Jaeger, C., Barkovits, K., Brockmann, K., Maetzler, W., et al. (2017). Distinct metabolomic signature in cerebrospinal fluid in early Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 32(10), 1401–1408. https://doi.org/10.1002/mds.27132.CrossRefGoogle Scholar